Matinas BioPharma Holdings, Inc.
MTNB NYSE· Pharmaceutical Preparations
Last close · Oct 27, 2026
$1.83
KIRA · Stoqly’s AI analyst, in plain words
- Matinas BioPharma Holdings, Inc. lost $10.3M in fiscal 2025.
Market cap
$11.7M
P/E
—
Revenue
—
Net income
−$10.3M
Free cash flow
—
Operating margin
—
Matinas BioPharma Holdings, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$10.3M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Matinas BioPharma Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Matinas BioPharma Holdings, Inc.
- CIK
- 0001582554
Matinas BioPharma Holdings, Inc. · MTNB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $3.2M | $1.1M | — | — |
| Revenue growth | −79.2% | 9,560.6% | −65.6% | — | — |
| Operating margin | −74,954.5% | −771.3% | −2,168.4% | — | — |
| Net income | −$23.3M | −$21.0M | −$22.9M | −$24.3M | −$10.3M |
| Net margin | −70,554.5% | −658.6% | −2,093.2% | — | — |
| Diluted EPS | −$0.11 | −$0.10 | −$5.28 | −$4.98 | −$2.00 |
| Cash | |||||
| Cash from operations | −$15.2M | −$19.2M | −$15.3M | −$15.9M | −$7.0M |
| Capital expenditure | $0.3M | $0.9M | $0.2M | — | — |
| Free cash flow | −$15.5M | −$20.0M | −$15.5M | — | — |
| FCF margin | −46,918.2% | −628.9% | −1,413.9% | — | — |
| Share count change | 6.7% | 3.2% | −98.0% | 12.0% | 12.5% |
| Debt and strength | |||||
| Cash and short-term investments | $49.6M | $28.8M | $13.8M | $7.3M | $4.0M |
| Shareholders' equity | $52.5M | $36.6M | $19.2M | $7.6M | $4.8M |
| Current ratio | 11.7x | 8.1x | 5.9x | 3.0x | 2.8x |
| Returns and quality | |||||
| Return on equity | −40.1% | −47.1% | −82.1% | −180.7% | −166.6% |
| Return on tangible equity | −49.2% | −65.0% | −154.0% | −455.0% | −426.6% |
| Piotroski F-score | 1 | 2 | 2 | — | — |
| Altman Z'' | 1.5 | −5.7 | −22.3 | −60.2 | −97.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Matinas BioPharma Holdings, Inc. · MTNB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.83 a share, the company is worth $11.7M.
Source: SEC EDGAR XBRL filings (CIK 0001582554). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.